GracoRoberts Acquires Sky Mart to Accelerate Latin American Expansion, Anchored by Miami Hub

Transaction Enhances MRO Scale, AOG Readiness, and Lubricants Market Leadership

ARLINGTON, Texas, Jan. 15, 2026 /PRNewswire/ -- GracoRoberts (gracoroberts.com) today announced the acquisition of Sky Mart (skymart.aero) to advance its international footprint in Latin America, leveraging the company's corporate headquarters in Miami as a gateway to the aerospace-rich Latin American region. The acquisition significantly bolsters GracoRoberts' reach into the $6.5B Latin American MRO market, scales its AOG capability, and offers its customers access to a considerable breadth of in-stock lubricants, amplifying the acquirer's already sound position as the largest, fastest, and most technically focused aerospace specialty chemicals distributor in the world.

The addition of Sky Mart to the GracoRoberts' portfolio expands its technical sales coverage throughout Latin America, the Caribbean, Florida, and portions of the US, while adding an additional 42,000 square feet of fulfillment centers in Miami, FL, San Antonio, TX, and Indianapolis, IN, and offering a rich stocking position for oils, greases, and fluids. Additionally, Sky Mart customers will benefit from access to GracoRoberts' extensive breadth of adhesives, composites, paints and coatings, a robust ecommerce presence for immediate product access, and a global technical sales team. These enhancements, coupled with a mutual focus on world-class quality, will add meaningful value to both companies' customer and supplier partners.

Jason Caldwell, President and CEO of GracoRoberts, commented on the acquisition. "We are thrilled to welcome the team from Sky Mart to the GracoRoberts' family of companies. This partnership strengthens our ability to serve the global aerospace community, especially in the important Latin America and Miami markets, with an enhanced stocking position, broader product offerings, and a scalable bolt-on ecommerce presence and AOG platform for an industry that requires speed and dependability." 

Juan Gregorio Robbin, Co-Founder and President of Sky Mart, also commented on the integration, and the decision to partner with GracoRoberts after four decades of family-owned operation. "At Sky Mart, our operating philosophy is simple and unwavering: stock the right products, deliver exceptional service, and get it right the first time. This guiding principle has earned us the trust of a loyal Latin and North American customer base, and by joining the GracoRoberts' family, we can deliver even more value to our customers."

Ana Maria Robbin, Co-Owner and Executive Vice President of Sky Mart, offered her perspective on the acquisition. "2025 marked Sky Mart's 40^th year in a business founded by our parents – our heroes – Gregorio and Lucy Robbin. They raised us to believe in the power of a vision, endless determination, and a deep spirit of service that defines our culture today, and I see these qualities in the team at GracoRoberts. I know the Sky Mart legacy will be upheld with care and purpose."

The leaders of both companies will collaborate to deliver a seamless, customer-focused transition that preserves each organization's culture and ensures no disruption to the business.

The acquisition of Sky Mart is supported by CM Equity Partners, the private equity sponsor of GracoRoberts and long-standing partner to its Executive Leadership Team (ELT). Under the leadership of President and CEO Jason Caldwell, the GracoRoberts ELT has significantly expanded the company's global footprint and accelerated its digital growth strategy through six acquisitions over the past seven years –  E.V. Roberts, Able Aerospace Adhesives, Silmid, SkyGeek, Pacific Coast Composites, and now Sky Mart – each enhancing value for its enterprise partners and the broader aerospace industry.

About GracoRoberts

Headquartered in Arlington, TX, GracoRoberts (www.gracoroberts.com) is the single largest, fastest, and most technically focused specialty chemicals distributor to serve the global aerospace market and is fully AS, ISO, and CMMC II certified. We serve the aerospace OEM, MRO, and defense segments, composites, electronics, and other advanced manufacturing industries. As a family of brands including Silmid, SkyGeek, and Pacific Coast Composites, we are authorized to distribute 3M, Airtech, Aeroshell, AkzoNobel, Eastman, Henkel, Hexcel, Huntsman, Isovolta, Momentive, PPG, Resin Formulators, Royco, Scott Bader, Sika, American Fiber & Finishing, Armite Lubricants, Arrow Solutions, B&J Rubber Products, Castrol, Chemetall, Contec, Deb Stoko, ITW Performance Polymers, Mask-Off, Master Fluid Solutions, Permabond, Reabrook Ltd, Rocol, Royal Adhesives, Socomore, and Zip-Chem, and can source thousands of other providers upon request. We differentiate by adding value: services include world-class ecommerce available through three websites (www.skygeek.com, www.silmid.com, and www.gracoroberts.com), global distribution, custom formulation, specialty packaging, vendor managed inventory, intermix and kitting services, defense logistics and compliance, export management services, and an on-staff Chemist, lab, and testing facility. GracoRoberts prides itself in delivering superior engineered materials with impeccable support to thousands of customers from more than 65 countries around the globe.

About Sky Mart

Headquartered in Miami, FL and founded in 1985 by Gregorio and Lucy Robbin with Co-Founder and President Juan Gregorio Robbin, Sky Mart (www.skymart.aero) has grown into an industry leading and well-recognized aerospace chemical, lubricant and specialty fluids stocking distributor. Sky Mart is now a second-generation Robbin family business serving thousands of customers across Latin America and North America. With over 40 years of global distribution experience, the company's philosophy is straight forward: stock the products, quote quickly, and offer fast, accurate, and on-time shipping. Today Sky Mart continues to invest in online and EDI trading platforms, and offers reliable and effective after-hours AOG service for the airline, MRO, and other aviation communities.

About CM Equity Partners

CM Equity Partners (www.cmequity.com), based in New York, NY, provides capital to the Federal services and aerospace and defense industries. For 30 years, CMEP has partnered with management teams to build enduring value by leveraging its industry knowledge, relationships, operating experience, and its corporate finance, M&A, and private equity expertise. CMEP employs an active and collaborative management approach, developing long-term strategic plans and guiding decisions on re-investment of profits to grow and broaden a company's revenue base and capabilities. CMEP's investments are structured with flexibility across a broad spectrum of the capital structure, including equity, structured equity, and mezzanine debt.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

GracoRoberts Acquires Sky Mart to Accelerate Latin American Expansion, Anchored by Miami Hub

HIGHLIGHTS

• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

• With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25^th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each by the data cut-off date.
• Seven participants received ⁶⁷Cu-SAR-bisPSMA and two participants were treated with a combination of ⁶⁷Cu-SAR-bisPSMA with enzalutamide.
• Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

• The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

• Six participants had at least two prostate specific antigen (PSA) results following ⁶⁷Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
• One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following ⁶⁷Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

• The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25^th of November 2025 and continue to show promising efficacy and a favourable safety profile of ⁶⁷Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to ⁶⁷Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their ⁶⁷Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to ⁶⁷Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of ⁶⁷Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of ⁶⁷Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of ⁶⁷Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial^[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer 'bis' structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

"We have already seen a glimpse of the effects of ⁶⁷Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of ⁶⁷Cu-SAR-bisPSMA.

"All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following ⁶⁷Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

"Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease."

About the SECuRE trial

The SECuRE trial (NCT04868604)^[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA. ⁶⁴Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of ⁶⁷Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)^[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of ⁶⁷Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)^[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants^[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of ⁶⁷Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial^[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of ⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease^[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact: